Back to Search
Start Over
Effect of Optimal Medical Therapy Before Procedures on Outcomes in Coronary Patients Treated With Drug-Eluting Stents.
- Source :
-
The American journal of cardiology [Am J Cardiol] 2016 Sep 15; Vol. 118 (6), pp. 790-796. Date of Electronic Publication: 2016 Jul 01. - Publication Year :
- 2016
-
Abstract
- It has not been established whether the achievement of optimal medical therapy (OMT) before implantation of a drug-eluting stent has a clinical benefit for patients with stable coronary artery disease (CAD). This study included 3,004 patients with CAD treated with drug-eluting stent from 123 Japanese participating centers. The achievement of OMT was defined as control of blood pressure <130/80 mm Hg, hemoglobin A1c <7.0%, and low-density lipoprotein cholesterol <100 mg/dl. The primary end point was target vessel failure, a composite of death related to the target vessel, myocardial infarction, or clinically driven revascularization at 24 months after stent implantation. Immediately before the procedure, only 548 patients (18.2%) had achieved all 3 target criteria (the achieved OMT group), whereas the remaining 2,456 patients failed to achieve one or more criteria (the non-OMT group). At 24 months, the incidence of target vessel failure was 7.0% in the achieved OMT group versus 10.0% in the non-OMT group (hazard ratio 0.68, 95% CI 0.48 to 0.96, p = 0.03). The incidence of non-Q-wave myocardial infarction was also lower in the achieved OMT group than in the non-OMT group (0.5% vs 1.5%, p = 0.08). Multivariate logistic regression analysis identified that hemoglobin A1c <7.0% was the only protective predictor of 24-month target vessel failure (odds ratio 0.56, 95% CI 0.43 to 0.73, p <0.01). In conclusion, this study demonstrated that in patients with stable CAD scheduled for stent implantation, achievement of OMT before percutaneous coronary intervention significantly reduced subsequent cardiac events. Achievement of OMT is still insufficient in modern clinical practice.<br /> (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Subjects :
- Adrenergic beta-Antagonists therapeutic use
Aged
Angiotensin Receptor Antagonists therapeutic use
Angiotensin-Converting Enzyme Inhibitors therapeutic use
Antibiotics, Antineoplastic therapeutic use
Antineoplastic Agents, Phytogenic therapeutic use
Blood Pressure
Cholesterol, LDL blood
Coronary Angiography
Coronary Artery Disease diagnostic imaging
Coronary Artery Disease epidemiology
Diabetes Mellitus drug therapy
Diabetes Mellitus epidemiology
Diabetes Mellitus metabolism
Dyslipidemias blood
Dyslipidemias drug therapy
Dyslipidemias epidemiology
Female
Glycated Hemoglobin metabolism
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Hypertension drug therapy
Hypertension epidemiology
Hypoglycemic Agents therapeutic use
Japan
Male
Middle Aged
Paclitaxel therapeutic use
Proportional Hazards Models
Prospective Studies
Randomized Controlled Trials as Topic
Risk Reduction Behavior
Sirolimus therapeutic use
Coronary Artery Disease therapy
Drug-Eluting Stents
Percutaneous Coronary Intervention methods
Platelet Aggregation Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1879-1913
- Volume :
- 118
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- The American journal of cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 27544742
- Full Text :
- https://doi.org/10.1016/j.amjcard.2016.06.050